Several Medications Show Promise for Treating Cannabis Use Disorder
A review of randomized controlled trials found multiple medications, including CBD, gabapentin, nabiximols, and others, showed superiority over placebo for cannabis use disorder, though all need further validation.
Quick Facts
What This Study Found
Across multiple pharmacological systems, CBD, gabapentin, galantamine, nabilone plus zolpidem, nabiximols, naltrexone, PF-04457845 (FAAH inhibitor), quetiapine, varenicline, and topiramate all showed some superiority over control conditions in RCTs for CUD. All were reported as safe and tolerable.
Key Numbers
About 1 in 5 cannabis users develop CUD, rising to 1 in 2 for daily users. CUD accounts for 0.69 million disability-adjusted life years globally. Ten medication classes showed some benefit across eight neurotransmitter systems.
How They Did This
Narrative review of randomized controlled trials examining pharmacological interventions for cannabis use disorder, organized by mechanism of action across cannabinoid, glutamatergic, GABAergic, serotonergic, noradrenergic, dopaminergic, opioidergic, and cholinergic systems.
Why This Research Matters
There is currently no FDA-approved medication for cannabis use disorder, despite the condition affecting roughly one in five cannabis users. This review maps the entire landscape of pharmacological candidates that have reached the RCT stage.
The Bigger Picture
The diversity of promising targets across multiple neurotransmitter systems suggests CUD is not a single-mechanism disorder. The field is moving toward combining pharmacotherapy with psychotherapy, and drug repurposing offers faster paths to clinical availability than new drug development.
What This Study Doesn't Tell Us
Narrative review without formal meta-analysis. Individual RCTs varied in sample size, follow-up duration, and outcome measures. Many trials had small samples. "Superiority over control" ranged from modest to meaningful effects.
Questions This Raises
- ?Which of these medications will prove most effective in larger confirmatory trials?
- ?Can combinations of medications targeting different systems produce better outcomes?
- ?Will personalized approaches based on patient characteristics improve treatment matching?
Trust & Context
- Key Stat:
- 10 medications showed some benefit for CUD across RCTs
- Evidence Grade:
- Narrative review synthesizing RCT evidence, which provides a broad overview but lacks the rigor of a systematic review or meta-analysis.
- Study Age:
- 2024 review
- Original Title:
- Emerging pharmacotherapy for the treatment of cannabis use disorder.
- Published In:
- Expert opinion on pharmacotherapy, 25(6), 695-703 (2024)
- Authors:
- Shamabadi, Ahmad(2), Arabzadeh Bahri, Razman, Karimi, Hanie, Heidari, Ehsan, Akhondzadeh, Shahin
- Database ID:
- RTHC-05701
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Are there medications for cannabis use disorder?
There is no FDA-approved medication yet, but this review found 10 medications (including CBD, gabapentin, nabiximols, and topiramate) that showed some benefit in randomized controlled trials.
What is the best treatment approach for CUD?
According to this review, combining pharmacotherapy with psychotherapy appears to be the optimal approach, tailored on a case-by-case basis.
Read More on RethinkTHC
- 30-days-without-weed
- 420-sober-survival-guide
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- CBT-cannabis-recovery
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-relapse-cycle-pattern
- cannabis-use-disorder-test
- cold-turkey-vs-taper-quit-weed
- creativity-without-weed-quitting-artist-musician
- cross-addiction-quit-weed-start-drinking
- dating-sober-after-quitting-weed
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- help-someone-quit-weed
- hobbies-after-quitting-weed
- how-to-quit-weed
- identity-after-quitting-weed
- is-weed-addictive
- is-weed-addictive-science
- journaling-weed-withdrawal
- leaving-stoner-culture-identity
- marijuana-anonymous-SMART-recovery-compare
- meditation-mindfulness-weed-withdrawal
- money-saved-quitting-weed-calculator
- one-year-sober-weed
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-and-alcohol
- quitting-weed-creativity
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-face-changes-skin
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- quitting-weed-weight-loss-gain
- rehab-for-weed-addiction-necessary
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- should-i-quit-weed
- signs-of-cannabis-use-disorder
- sober-music-festival-concert-without-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-05701APA
Shamabadi, Ahmad; Arabzadeh Bahri, Razman; Karimi, Hanie; Heidari, Ehsan; Akhondzadeh, Shahin. (2024). Emerging pharmacotherapy for the treatment of cannabis use disorder.. Expert opinion on pharmacotherapy, 25(6), 695-703. https://doi.org/10.1080/14656566.2024.2353638
MLA
Shamabadi, Ahmad, et al. "Emerging pharmacotherapy for the treatment of cannabis use disorder.." Expert opinion on pharmacotherapy, 2024. https://doi.org/10.1080/14656566.2024.2353638
RethinkTHC
RethinkTHC Research Database. "Emerging pharmacotherapy for the treatment of cannabis use d..." RTHC-05701. Retrieved from https://rethinkthc.com/research/shamabadi-2024-emerging-pharmacotherapy-for-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.